Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2020 Jun 9;10:9586. doi: 10.1038/s41598-020-66543-3

Author Correction: Downstream Products are Potent Inhibitors of the Heparan Sulfate 2-O-Sulfotransferase

David F Thieker 1,2, Yongmei Xu 3, Digantkumar Chapla 2, Chelsea Nora 4, Hong Qiu 2, Thomas Felix 1,2, Lianchun Wang 1,2, Kelley W Moremen 1,2, Jian Liu 3, Jeffrey D Esko 4, Robert J Woods 1,2,
PMCID: PMC7280261  PMID: 32514069

Correction to: Scientific Reports 10.1038/s41598-018-29602-4, published online 07 August 2018

In this Article, the authors neglected to include some potential conflicts of interest.

The Competing Interests section should read:

“J. L. is a founder of Glycan Therapeutics. D.F.T., Y.X., D.K., C.N., T.F., H.Q., L.W., K.W.M., R.J.W. declare no competing interests. J.D.E. is a co-founder of TEGA Therapeutics. J.D.E. and The Regents of the University of California have licensed a University invention to and have an equity interest in TEGA Therapeutics. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies.”


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES